Esperion Therapeutics Terminates Material Definitive Agreement
Ticker: ESPR · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $304,656,180, $517,915,506, $343,750,000.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-definitive-agreement, filing
Related Tickers: ESPR
TL;DR
Esperion just axed a big deal, filing an 8-K to spill the beans.
AI Summary
On June 27, 2024, Esperion Therapeutics, Inc. announced the termination of its previously entered material definitive agreement with an unnamed party. The company also reported on other events and filed financial statements and exhibits as part of this 8-K filing.
Why It Matters
The termination of a material definitive agreement can signal a shift in business strategy or a breakdown in negotiations, potentially impacting future operations and financial performance.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can introduce uncertainty regarding future business relationships and financial projections.
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Registrant
- June 27, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of incorporation
- 3891 Ranchero Drive, Suite 150 (address) — Principal executive offices
- Ann Arbor, MI (location) — City and State of principal executive offices
- 48108 (zip_code) — Zip code of principal executive offices
- (734) 887-3903 (phone_number) — Registrant's telephone number
FAQ
What was the nature of the material definitive agreement that was terminated?
The filing does not specify the nature of the material definitive agreement that was terminated, only that it was entered into and subsequently terminated.
When was the material definitive agreement entered into?
The filing does not provide the date when the material definitive agreement was initially entered into, only that it was terminated on June 27, 2024.
Are there any financial implications mentioned regarding the termination?
The filing does not detail specific financial implications arising from the termination of the agreement.
Who was the other party to the material definitive agreement?
The filing does not disclose the identity of the other party involved in the terminated material definitive agreement.
What other events are reported in this 8-K filing?
In addition to the termination of a material definitive agreement, the filing also reports on the entry into a material definitive agreement and other events, along with financial statements and exhibits.
Filing Stats: 910 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2024-06-28 08:03:14
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market LLC
- $304,656,180 — aser, and the Purchaser purchased for US$304,656,180, a portion of the royalties payable on
- $517,915,506 — of the Purchase Price (equivalent to US$517,915,506). Following receipt of such amount, 100
- $343,750,000.00 — the Purchasers, a payment in cash of US$343,750,000.00 (the "Repurchase Consideration"). Follo
Filing Documents
- espr-20240627.htm (8-K) — 32KB
- exhibit991salesroyaltypres.htm (EX-99.1) — 14KB
- 0001628280-24-030403.txt ( ) — 176KB
- espr-20240627.xsd (EX-101.SCH) — 2KB
- espr-20240627_lab.xml (EX-101.LAB) — 22KB
- espr-20240627_pre.xml (EX-101.PRE) — 13KB
- espr-20240627_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated June 2 8 , 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 28, 2024 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer